Skip to content

Insider · CIK 0001709690

Reinhard J. Ambros

director

Files at RNTX (Rein Therapeutics, Inc.). First filing -, latest -.

In brief

Reinhard J. Ambros files SEC Form 4 as director at RNTX (Rein Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Reinhard J. Ambros has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 2 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jul 23, 2025RNTX
Rein Therapeutics, Inc.
AGrant or award
Stock Option (right to buy)derivative
+17,500$0.00$017,500Jul 23, 2025
Dec 2, 2024RNTX
Rein Therapeutics, Inc.
AGrant or award
Stock Option (right to buy)derivative
+35,000$0.00$035,000Dec 6, 2024

Questions about Reinhard J. Ambros

Answered from the filings on this page, as of the latest one.

Is Reinhard J. Ambros buying or selling?

Reinhard J. Ambros has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Reinhard J. Ambros's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Reinhard J. Ambros has 0.

Where does Reinhard J. Ambros file Form 4?

Reinhard J. Ambros has filed Form 4 at RNTX (Rein Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Reinhard J. Ambros: insider trades and track record | InsiderTell